Literature DB >> 1352988

Impairment of carbamazepine-10, 11-epoxide elimination by valnoctamide, a valpromide isomer, in healthy subjects.

F Pisani1, A Fazio, C Artesi, G Oteri, E Spina, T Tomson, E Perucca.   

Abstract

The effect of the valpromide isomer valnoctamide (VCD, 200 mg three times daily for 8 days), an over-the-counter tranquillizer, on the elimination kinetics of a single oral dose of carbamazepine-10, 11-epoxide (CBZ-E, 100 mg) was investigated in healthy subjects. During VCD treatment, the half-life of CBZ-E was prolonged significantly compared with control (19.7 +/- 6.7 h vs 6.9 +/- 2.0 h, means +/- s.d., P less than 0.01), and its oral clearance decreased four-fold (from 109.6 +/- 30.7 to 28.8 +/- 11.1 ml h-1 kg-1, P less than 0.01). These findings indicate that VCM, like valpromide, strongly inhibits epoxide hydrolase in vivo.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1352988      PMCID: PMC1381382          DOI: 10.1111/j.1365-2125.1992.tb04114.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

1.  Structure-pharmacokinetic relationships in a series of short fatty acid amides that possess anticonvulsant activity.

Authors:  A Haj-Yehia; M Bialer
Journal:  J Pharm Sci       Date:  1990-08       Impact factor: 3.534

2.  A clinical study in the use of valmethamide, an anxiety-reducing drug.

Authors:  W STEPANSKY
Journal:  Curr Ther Res Clin Exp       Date:  1960-05

3.  Sodium valproate and valpromide: differential interactions with carbamazepine in epileptic patients.

Authors:  F Pisani; A Fazio; G Oteri; C Ruello; C Gitto; F Russo; E Perucca
Journal:  Epilepsia       Date:  1986 Sep-Oct       Impact factor: 5.864

4.  Interaction of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine, with valproate: a pharmacokinetic study.

Authors:  F Pisani; M Caputo; A Fazio; G Oteri; M Russo; E Spina; E Perucca; L Bertilsson
Journal:  Epilepsia       Date:  1990 May-Jun       Impact factor: 5.864

5.  Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects.

Authors:  M Bialer; A Haj-Yehia; N Barzaghi; F Pisani; E Perucca
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

6.  Inhibition of epoxide hydrolase by valproic acid in epileptic patients receiving carbamazepine.

Authors:  D K Robbins; P J Wedlund; R Kuhn; R J Baumann; R H Levy; S L Chang
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

7.  Valpromide/carbamazepine and risk of teratogenicity.

Authors:  G M Pacifici; T Tomson; L Bertilsson; A Rane
Journal:  Lancet       Date:  1985-02-16       Impact factor: 79.321

8.  Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: in vitro/in vivo correlation.

Authors:  B M Kerr; A E Rettie; A C Eddy; P Loiseau; M Guyot; A J Wilensky; R H Levy
Journal:  Clin Pharmacol Ther       Date:  1989-07       Impact factor: 6.875

9.  Effect of valpromide on the pharmacokinetics of carbamazepine-10, 11-epoxide.

Authors:  F Pisani; A Fazio; G Oteri; E Spina; E Perucca; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  1988-05       Impact factor: 4.335

10.  Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers.

Authors:  M Bialer; A Rubinstein; I Raz; O Abramsky
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

View more
  3 in total

Review 1.  Diverse mechanisms of antiepileptic drugs in the development pipeline.

Authors:  Michael A Rogawski
Journal:  Epilepsy Res       Date:  2006-04-18       Impact factor: 3.045

Review 2.  Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.

Authors:  E Spina; F Pisani; E Perucca
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

Review 3.  Can we develop improved derivatives of valproic acid?

Authors:  M Bialer; A Haj-Yehia; K Badir; S Hadad
Journal:  Pharm World Sci       Date:  1994-02-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.